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Summary Rees and Convit antigens prepared from armadillo-derived Mycobac-
terium leprae were used for skin testing in two leprosy endemic villages to
understand their use in the epidemiology of leprosy. In all, 2602 individuals
comprising 202 patients with leprosy detected in a prevalence survey, 476
household contacts and 1924 persons residing in non-case households were tested
with two antigens. There was a strong and positive correlation ( r = 0.85) between
reactions to the Rees and Convit antigens. The distribution of reactions was
bimodal and considering reactions of 12 mm or more as ‘positive’, the positivity
rate steeply increased with the increase in age. However. the distributions of
reactions to these antigens in patients with leprosy. their household contacts and
persons living in non-case households were very similar.
These results indicate that Rees and Convit antigens are not useful in the
identification of M. leprae infection or in the confirmation of leprosy diagnosis in
a leprosy endemic population with a high prevalence of nonspecific sensitivity.
Introduction
There are several unanswered questions in the epidemiology of leprosy. There has been a
long-felt need for a test that could recognize infection with Mycobacterium leprae and
thereby serve as a marker for the postinfection phase.1 Lepromin testing does not fulfil
this need because studies2 have shown lepromin positivity in leprosy non-endemic
populations, as well as its occurrence on account of other mycobacterial infections. Also,
it is widely believed that the late lepromin reaction (Mitsuda reaction). which serves as a
tool to classify patients with leprosy.3 helps to identify persons susceptible to the
lepromatous form of leprosy.4,5 Reaction to lepromin is expected to be negative in such
persons. although infected with M. leprae. In addition. lepromin has been documented as
a miniature vaccine.6 Drs Rees and Convit have prepared soluble antigens from M. leprae
of armadillo origin, known as Rees and Convit antigens, which have been used in
different parts of the world to understand their use in the epidemiology of leprosy.7 Rees
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and Convit antigens were supplied to our Unit by the IMMLEP programme of the World
Health Organization. After obtaining the necessary clearance from the Drugs Controller
of India, we used these antigens for skin testing in a leprosy endemic population, and our
findings are reported here.
This study was particularly relevant to us as our Unit is proposing to undertake a
leprosy vaccine trial. Identification of M. leprae infected population and also the
population at risk of suffering from leprosy, particularly the multibacillary form, will be
highly relevant in a leprosy vaccine trial situation.
Materials and methods
This work was done during the period February to April 1987, in a population of 2602
persons from two leprosy endemic villages in Sriperumbudhur Taluk of Chengalpattu
District in Tamil Nadu. Initial screening for leprosy prevalence in this population was
done by trained paramedical workers. All the suspects and cases of leprosy detected by the
paramedical workers were reexamined by a medical officer or one of two senior technical
assistants, who had more than 15 years experience and had been trained in standardized
clinical diagnosis of leprosy. Diagnosis of leprosy was based on clinical parameters and
was supported by skin-smear examination for acid-fast bacilli. Patients were classified
into different types following the system adopted by the Indian Association of 
Leprologists.8 In Chengalpattu District, BCG immunization was not undertaken by the
health services, as this district was kept free from BCG coverage. However, each person
was examined by a trained technician for the presence or absence of a BCG scar and the
result recorded.
In the various observations reported here, the following antigens were used for skin
tests:
(1) Tuberculin PPD (RT 23, 1 TU per dose) from BCG Vaccine Laboratory, Madras.
(2) Rees antigen (Batch CD-19), supplied by Dr Rees (1 mcg protein per dose).
(3) Convit antigen (Batch SA-IND, 1.1686) supplied by Dr Convit (dose as
standardized by Dr Convit).
For skin testing and reading standard procedures were followed.9 Skin testing was
done by an assessed tester by superficial intracutaneous injections of 0.1 ml of antigens.
Tuberculin test was given on the mid-volar side of the left forearm. Rees and Convit
antigens were randomly allocated to the upper dorsum of the two forearms. Reactions to
Rees and Convit tests were read after 48 hr and that to the tuberculin test after 72 hr. The
interval of 48 hr for Rees and Convit antigen readings was based on our previous
experience, where we took serial readings after 24, 48 and 72 hr.10 Tuberculin skin tests are
routinely read after 72 hr.9 Transverse diameters of the indurations were measured in
millimetres, by an experienced reader. The same tester and reader were used throughout
the study. Skin testing was done in all age and sex groups, excluding infants up to the age
of 1 year.
After initial standardization studies for skin testing,10 about 2400 individuals from
one village (TT01) were tuberculin tested and read. Three months later, Rees and Convit
antigen skin tests were performed in the same population. Data from 888 individuals who
were tested and read for all the three skin test antigens, tuberculin, Rees and Convit, has
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been used to compare the skin test reactions to these three antigens. In this village 126
individuals were tested and read for the Rees and the Convit antigens, but not for
tuberculin.
Skin testing was performed using Rees and Convit antigens in an adjoining village
(TT02). Tuberculin was not used in this village.
The skin test responses to the Rees and the Convit antigens were studied in the
population from both the villages with respect to age, sex, clinical evidence and type of
leprosy, as well as according to the household contact status with leprosy patients. From
village TT01, 96 patients, 143 household contacts of these patients and 812 individuals
living in households without a case of leprosy were test read. From village TT02, these
figures were 106, 333 and 1112 respectively. In all, 2602 individuals. comprising 202
clinically diagnosed patients with leprosy during the prevalence survey. 476 household
contacts of these patients and 1921 individuals living in households without a case of
leprosy were tested and read for the Rees and Convit antigens. Of the 476 household
contacts, 444 individuals were contacts of paucibacillary cases and 32 were contacts of
multibacillary cases.
Results
COMPARISON OF REACTIONS TO REES AND CONVIT ANTIGENS AND TUBERCULIN
Correlation between reactions to Rees and Convit antigens in 888 individuals from village
TT01 is presented in Table 1. There was a strong and positive correlation between the two
indurations with a correlation coefficient of 0.85 which was statistically highly significant
(p < 0.001). However, the mean size of reaction to Rees antigen (14.1 mm) was slightly
higher than that to the Convit antigen (12.8 mm). The mean difference between the two
reaction sizes was 1.2 mm (p < 0.001). This relationship was similar in different age and
sex groups as well as in patients and their household contacts. The relationship was also
similar in the 1551 individuals from village TT02 (correlation coefficient 0.80; p < 0.001).
Similar comparisons were made between reactions to Rees antigen and tuberculin. as
well as between reactions to Convit antigen and tuberculin in the 888 individuals from
Table 1. Correlation between reactions to Rees and Convit antigens in
888 individuals from village TT01
Reaction Reaction to Convit antigen (mm)
to Rees
antigen 0-3 4-7 8-11 12-15 16-19 20-23 24-27 Total
00-03 14 4 5 – 1  – – 24
04-07 11 140 18 3 1 1 – 174
08-11 1 35 46 18 4 1 – 105
12-15 3 14 35 77 23 5 – 157
16-19 2 5 11 75 126 13 1 233
20-23 – – 2 17 91 35 7 152
24-27 – – – – 7 25 10 42
28-31 – – – – – – 1 1
Total 31 198 117 190 353 80 19 888
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village TT01 (Table 2). It was seen that there was a positive but weak correlation between
reactions to Rees antigen and tuberculin (correlation coefficient 0.44; p < 0.01) as well as
between reactions to Convit antigen and tuberculin (correlation coefficient 0.44; p < 0.01).
The mean difference in sizes of reaction to Rees antigen and tuberculin was 2.7 mm
(p <0.001) and that between Convit antigen and tuberculin was 1.5 mm (p <0.001).
Bimodality in the frequency distributions was seen for all the three antigens with the
antimode at 8-11 mm (Figure 1). In analogy with tuberculin reactions, considering the
first curve with reactions of 0-11 mm to represent ‘reaction negative’ individuals and the
second curve with reactions of 12 mm and above to represent ‘reaction positive’
individuals, the proportions with ‘positive’ reactions to the Rees and the Convit antigens
were 66% and 61% respectively. This difference was statistically significant (p < 0.05).
Comparison between reactions to the Rees antigen and tuberculin showed that, in
general, Rees antigen positivity was higher in the tuberculin positive individuals. Patients
of leprosy as well as individuals in whom BCG scars were present were excluded for the
sake of this comparison. The results are based on skin test reactions in 702 individuals. It
was seen that in the younger age group of 1-9 years, the Rees antigen positivity was much
higher among tuberculin positives (66%) as compared to that among tuberculin negatives
(24%). This difference was statistically highly significant (p <0.001). However, in the
higher age groups the differences were small and not statistically significant.
In the village TT01, 126 individuals who were not tested for tuberculin were tested and
read for the Rees and Convit antigens. Distributions of reactions to the Rees and the
Convit antigens in these individuals were very similar to the ones in the 888 tuberculin
Table 2. Correlation between reactions to Rees. Convit antigens and
tuberculin in 888 individuals from village TT01
Reaction
(mm) to
Reaction to tuberculin (mm)
0-3 4-7 8-11 12-15 16-19 20-23 24-27 Total
Rees antigen
00-03 5 3 3 5 6 2 – 24
04-07 59 79 3 10 14 5 4 174
08-11 21 42 7 8 16 10 1 105
12-15 10 50 21 29 33 12 2 157
16-19 12 19 28 48 69 21 6 233
20-23 4 12 9 40 66 18 3 152
24-27 1 2 3 7 23 6 – 42
28-31 – – 1 – – – – 1
Total 112 237 75 147 227 74 16 888
Convit antigen
00-03 4 6 4 5 8 4 – 31
04-07 68 87 4 12
10
21 2 4 198
08-11 14 54 10 17 11 1 117
12-15 13 52 24 41 38 21 1 190
16-19 9 31 25 60 95 23 10 253
20-23 4 6 7 16 36 11 – 80
24-27 – 1 1 3 12 2 – 19
Total 112 237 75 147 227 74 16 888
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Figure 1. Distribution of the 888 persons by size of reaction to Rees and Convit antigens and tuberculin.
tested individuals. The mean reaction sizes for the Rees antigen were 14.3 mm and 14.1
mm and that for the Convit antigen 12.9 mm and 13.8 mm in the two groups of 126 and
888 individuals respectively. The proportion of individuals with positive reactions were
also very similar in the two groups. 67.5% of the tuberculin tested and 65.9% of those not
tested with tuberculin gave positive reactions to the Rees antigen. Similar figures for the
Convit antigen were 62.7% and 61.0% (p > 0.5, in both cases).
INFLUENCE OF BCG SCAR ON REES ANTIGEN POSITIVITY
The 2602 individuals from the two villages who were Rees antigen tested and read were
also examined for the presence of a BCG scar. As mentioned earlier. this area was kept
free from routine BCG vaccination and as such the prevalence of BCG scars was low. By
the age of 10 years a high proportion of persons (68%) were showing Rees antigen
positivity, and only children aged 1-9 years were considered in the study of the influence
of BCG scars on the Rees antigen positivity. Of the 688 children aged 1-9 years who had
been examined for BCG scars, 79 (11.5%) had BCG scars. Eighteen (32.8%) of the 79 with
a BCG scar and I73 (28.4%) of the 609 without a BCG scar showed Rees positivity. This
difference was not statistically significant (p > 0.2).
It was also seen that the tuberculin positivity was similar in persons with a BCG scar
and in those without. Considering the age group 1-9 years, 15 (11.2%) of 134 with a BCG
scar and 54 (10.5%) of 515 without a BCG scar showed positive reactions to tuberculin
(p > 0.9).
REES SKIN  TEST POSITIVITY IN PATIENTS AND NON-PATIENTS OF LEPROSY
Skin test results from the two villages with respect to the positivity to the Rees antigen was
marginally different, It was slightly higher in village TT01 as compared to that in village
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TT02. This difference was consistent in different groups of individuals (Table 3).
However, distributions of reactions to the Rees antigen in both the villages were similar
and bimodal with the antimode at 8-11 mm. Therefore, the information from the 2602
individuals in the two villages is merged for studying the pattern of reactions to Rees’
antigen. Considering 12 mm and above as the criterion for positivity, 11.9%, 41.8%,
68.0% and 76.9% were ‘positive’ to Rees antigen in the age groups 1-4, 5-9, 10-14 and
15+ years, respectively. Figure 2 provides the information on Rees skin test positivity in
different age groups separately for the 202 patients with leprosy, 476 household contacts
of these patients and 1924 individuals living in households without leprosy.
Of the 202 patients. only 14 (7%) had multibacillary forms of leprosy and thus only 32
of the 476 household contacts were contacts of patients with multibacillary leprosy.
Fourteen (43.8%) of the 32 contacts with multibacillary leprosy and 270 (60.8%) of the
444 contacts of patients with paucibacillary leprosy were ‘positive’ to the Rees antigen.
This difference was not statistically significant (0.10 >p> 0.05). The Rees antigen
positivity was 22   .2% (4 of 18) and 41.2% (84 of 204) in the age group 1-14 years and
71.4% (10 of 14) and 77.5% (186 of 240) in the age group 15+ years in the contacts of
multibacillary and paucibacillary cases respectively. These differences were also not
statistically significant t p > 0.1).
Considering the 202 patients with leprosy. frequency distributions of Rees antigen
skin indurations are given separately for the different types of leprosy in Table 4. The
bimodality of the distribution is observed in patients with leprosy as well. This bimodality
is also seen in patients with tuberculoid and the borderline tuberculoid types. Amongst 14
patients with borderline or lepromatous leprosy, 4 showed reactions of 12 mm or more
though there was no tendency for bimodal distribution. Since the significance of smaller
reactions to the Rees antigen may be different from that to tuberculin. while comparing
the results of Rees antigen test in patients and non-patients of leprosy, the entire range of
reactions were considered. Thus, when the frequency distributions (age and sex
Table 3. Rees antigen positivity (%0 with 12+ mm) according to age in the two villages
Age group (in years)
Village Populat ion 1-4 5-9 10-14 15-24 2 5 - 3 4  3 5 * Total*
TT01 Patients
Contacts
Others
(2 )
47.8
(11)
12.7 50.0
(23) (24)
13.1 43.5
(110) (123)
TT02 Patients
Contacts
Others
( 4 )
50.1
(10)
11.0 49.6
(53) (54)
11.8 35.6
(136) (149)
63.7
(15)
61.8
(16)
70.5
(124)
87.3
(11)
51.4
(52)
67.9
(140)
80.0 93.1 78.2 66.5
(20) (16) (32) (96)
78.4 100.0 78.6 69.1
(27) (20) (33) (143)
79.8 84.9 85.1 69.0
(152) (116) (187) (812)
70.7 74.3 67.0
(24) (18) (39)
74.9 91.0 67.7
(60) (32) (82)
73.1 76.1 74.8
(226) (147) (314) (
61.2
(106)
62.9
(333)
61.9
1112)
Figures in parentheses give denominators.
* Age-sex standardized.
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Figure 2. Rees skin test positivity (%)  in patients, contacts and others by age.
Table 4. Distribution of leprosy patients by size of reaction to Rees’
antigen
Type of
leprosy
Size of reaction (mm)
0-3 4-7 8-11 12-15 16-19 20-23 24-27 Total
Neuritic 2 5 2 5 3 6 2 25
Indeterminate 1 8 3 13 8 5 3 41
TT and BT 3 16 10 30 32 19 12 122
BL and LL 3 3 4 2 1 1 0 14
Total 9 32 19 50 44 31 17 202
standardized) of Rees antigen indurations for the patients. contacts and the general
population (excluding patients of leprosy and contacts) from the two villages were
considered. the similarity in the distributions was very striking (Table 5). All the three
groups gave a bimodal distribution with the antimode at 8-11 mm (Figure 3).
Discussion
Preparation of M. leprae soluble antigens was being viewed as a promising development
to detect subclinical M. leprae infections. Studies in Venezuela by Convit indicated that
the soluble antigen developed by him from the armadillo-derived M. leprae would meet
the requirements and would be sufficiently sensitive and specific for epidemiologicat field
studies.11 IMMLEP-TDR under the World Health Organization encouraged studies
using these antigens in several worldwide areas.11
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Table 5. Proportion (%)* of patients and nonpatients of leprosy by size of
reaction to Rees antigen
Reaction to Rees (mm)
Population 0-3 4-7 8-11 12-15 16-19 20-23 24-27 28-31 Total
Patients 4.0 23.9 8.7 22.3 20.5 13.2 7.4 – 100
Contacts 3.6 19.6 12.0 18.1 23.8 18.8 3.6 0.5 100
Others 4.2 19.7 11.6 18.1 25.9 15.7 4.6 0.2 100
* Age-sex standardized rates.
Figure 3. Distributions (age-sex) of patients. contacts and others by size of reaction to Rees antigen.
In the findings reported here, care was taken to avoid the methodological problems on
account of batch-to-batch variations and variations due to multiple testers and readers.
We found a positive and very high degree of correlation between reactions to the Rees and
Convit antigens. The findings were similar in different age and sex groups as well as in
patients and contacts of the patients. Since the two antigens were calibrated to different
standards, the mean difference of 1.2 mm in the skin-test reactions to the Rees and Convit
antigens may just be a dose effect and as such not biologically significant. For the various
results presented, for patients, contacts and population, the information is given on the
Rees antigen, but the results were very similar for the Convit antigen as well.
In the study reported here, we used CD-19 batch for the Rees antigen and SA-IND. l-
16-86 for the Convit antigen. We have observed earlier. in two independent experiments.
that the correlation between reactions to two different batches (CD-19, CD-73) of the
Rees antigen was much stronger (r = 0.81 and 0.77) than that observed for two different
batches (SA-IND, 1-16-86 and IB-Lote, 4-6-87) of the Convit antigen (r =0.53 and
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0.66).10 One study12 (observed a positive correlation (r = 0.7) between postvaccination
reactions to Rees (CD- 19) and WEL-I (an antigen prepared using the protocol for Convit
antigen) antigens although the responses to WEL-1 antigen were uniformly lower than
that to the Rees antigen. They also found that the WEL-I antigen did not produce pre-
vaccination induration in the vast majority of the individuals tested. The protein content
of WEL-I and Rees antigens was 0.5 mcg and 1.0 mcg per dose, respectively.12 It is
difficult to say whether the high degree of correlation observed by us between reactions to
Rees and Convit antigens was limited to the particular batches used or the observed
dissimilarity on the other occasions was due to variations in the calibration procedures for
the Convit antigen. Considering the magnitude of positive correlation observed between
reactions to the two antigens, both by us and by Ponnighaus and Fine, the observed
differences might be on account of dose or calibration effect.
In the 888 individuals skin tested with Rees, Convit and tuberculin antigens, a low
level of positive correlation was seen between reactions to the Rees antigen and
tuberculin, as well as between reactions to the Convit antigen and tuberculin. It was seen
that this association was significant in the younger age group of 1-9 years only. However,
even in this age group as many as 24%   of children who were tuberculin negative showed
positive reactions to the Rees antigen. It appears that the tuberculin status of an
individual would affect the Rees antigen positivity only marginally and also only in the
younger children in the study area. Thus tuberculin positivity was at most only partially
responsible in producing cross-sensitization to the Rees antigen. It was also seen that
prior tuberculin testing did not seem to influence the pattern of reactions to a subsequent
test with the Rees antigen.
The differences observed in the two villages with respect to the Rees and the Convit
antigen reactions were marginal, though statistically significant (Table 3). The frequency
curves, however, followed the same pattern and in all probability the observed difference
did not have any biological significance.
The BCG scar status did not influence reaction to Rees antigen in our study. Convit
and Zuniga in Venezuela and Fine and Ponnighaus in Malawi found cross-sensitization
on account of BCG scar status.7 One study13 in Sri Lanka did not find any such influence,
another study14 in Agra, India observed that the previous BCG scar status did not
influence the leprosin-A (Rees antigen) results in the children studied. However, in a
prospective study, they found an increase in the Rees antigen positivity following BCG
vaccination.14 Also, it was seen in our study that even the tuberculin reactions did not
depend. on the BCG scar status. However, it should be noted that the population in
Chengalpattu District was kept free from BCG vaccination programme, and the
proportion of persons with a BCG scar was less than 10%. The practice generally
followed in India is BCG vaccination at birth. The waning of tuberculin sensitivity after
BCG has been documented in Chengalpattu District. 15-16 In a study in Madras city, it was
observed that the post-BCG tuberculin sensitivity in newborn babies waned considerably
over a period of 12 months. 17 In a study in Sri Lanka involving 740 healthy children given
a BCG vaccination in their first month, it was seen that 80% of the children showed
tuberculin anergy in spite of having a visible scar. 18 A similar waning effect may also be
expected on cross-sensitization, if any, for the Rees antigen.
We obtained a consistent bimodal pattern with both the Rees and the Convit antigens
(Figure 1). Based on this pattern, we considered reactions of 12 mm or more as ‘positive’.
With this cut-off point, 73% (138 of 188) of patients with paucibacillary leprosy were Rees
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antigen positive while 71% (10 of 14) of patients with multibacillary leprosy were Rees
antigen negative. The cut-off point used by various workers for defining positivity have
been different. In the Malawian studies, despite observing a clear bimodal distribution,
the investigators arbitrarily called reactions of > 5 mm as ‘positives’.12 The criterion for
positivity adopted for the Convit antigen reactions by Convit and his colleagues was 10
mm or more.19 Stanford and Lema considered indurations of 2 mm or more as a positive
response.20 Different definitions adopted by various investigators will certainly contribute
to the observed differences with respect to positivity. The frequency distributions of
reactions to the soluble antigens appear to follow different patterns in different
areas.13,21,22 Prevalence of environmental mycobacteria and other organisms, prior
vaccination with BCG as well as infection with M. leprae are some of the likely causes to
affect these distribution patterns.
Results from earlier studies indicate that these antigens might be useful for
classification of leprosy and in identifying the population at a high risk for
multibacillary leprosy. Data from Malaysia and India showed that patients with
lepromatous leprosy were uniformly negative to Rees antigen while tuberculoid patients
were positive.7 Samuel et al. have concluded from their work in five different countries,
namely India, Uganda, Kenya, Nepal and Bhutan, that the Rees antigen (Leprosin-A)
reactions were positive in the high resistant forms of leprosy and were negative in low
resistant lepromatous forms.23 Ponnighaus and Fine also found that 80% of untreated
paucibacillary patients with leprosy in Malawi gave positive skin test reactions ( > 5 mm)
to a Rees-type antigen, whereas, only 35 % of a sample of treated patients were positive.
All the multibacillary patients, although only a few, were skin test negative.7 Convit had
reported similar results with his antigen in Venezuela. These findings with the soluble
antigens are similar to the Mitsuda reaction to lepromin test in leprosy patients.
In the present study we noticed that Rees antigen positivity was 64.0%, 70.7% and
76.2% in neuritic, indeterminate and the TT-BT groups of patients respectively. In the
BL-LL groups of patients, however, it was only 286%. Thus the skin test results in the
study patients from South India followed a similar pattern as reported by other workers.
However, the capacity of the Rees antigen to classify the leprosy patients into two groups,
paucibacillary and multibacillary, was limited and the dividing line was blurred. Fifty
(27%) of the 188 paucibacillary patients were ‘negative’ and 4 (29%) of the 14
multibacillary patients were ‘positive’ to the Rees antigen test.
We observed that the distributions of reactions to both the Rees and Convit antigens
were bimodal. This observation was true for patients with leprosy, their household
contacts, as well as the general population. It was seen that the reaction positivity to the
Rees antigen increased sharply with the increase in age in both males and females.
Generally, the reaction positivity was higher in males than in females. It is to be expected
that the risk of infection will increase with age. However, it is difficult to conceive such a
steep rise with age on account of the new infections due to M. leprae alone. The similarity
in the distributions of reactions to Rees antigen in patients with leprosy. their household
contacts and general population became strikingly demonstrable when the age and sex
standardized proportions in different reaction sizes were considered (Table 5 and Figure
3). The Rees reaction positivity was also very similar in patients, contacts of both
paucibacillary and multibacillary patients with leprosy, and general population in
different age groups (Figure 2). In this respect, our results are different from the
observations of Convit and Zuniga in Venezuela. Convit and Zuniga extensively used the
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M. leprae soluble antigen (Convit antigen) in Venezuela. Their initial objective was to
have a test comparable to the lepromin test. They also hoped that the Convit antigen
would be useful to determine prevalence and incidence of infection due to M. leprae. They
found that the prevalence of Convit skin test positivity correlated with the level of
prevalence of leprosy in the population. Only 3.5% individuals were positive in
nonendemic areas of Chile compared to 46% positives in endemic areas of Venezuela.
Contacts of leprosy patients showed higher levels of positivity than that in the general
population.7 Extensive studies have also been done in Malawi using the M. leprae soluble
antigens. Fine et al. found a clear bimodal distribution of the skin reactions in the
Northern Malawi population endemic for leprosy. Based on the rising prevalence rate of
positivity with age, they postulated that the skin tests were specific for some mycobacter-
ial experience.21
In a study in Bangladesh, Cree et al. observed that the Rees antigen (CD-19) positivity
( > 5 mm) was similar in 78 household contacts of untreated patients, 34 untreated
paucibacillary patients and 50 randomly selected indigenous subjects. It was 56.6%,
56.3% and 55.6% in the three groups respectively.24
In a population based study in Sri Lanka. Pinto et al. did not find any statistically
significant changes in Rees’ antigen (CD- 19) positivity with respect to age, sex, race or
BCG vaccination status.13
It is difficult to explain the differences observed in the results of these studies.
However, the possible reasons could be the use of different batches of antigens. prevalence
of different levels of leprosy endemicity and nonspecific sensitization, as well as the
differences in the populations studied.
Variations observed in some of the studies mentioned above could be explained as due
to the substantial amount of variations in the skin reactions produced by different batches
of these antigens. Such batch-to-batch variations have been observed and documented by
us.10 Similar observation is also reported by Fine et al. in the Malawi studies.21
Considerable batch-to-batch variability of skin test antigens was also observed in
Venezuela.7 Rees antigen batch CD-19 was used by us in the study reported here. This
batch has been extensively used in different parts of the world. Pinto et a1., 13 Cree et al. 24
and Ponnighaus & Fine12 used the same batch in their studies in Sri Lanka, Bangladesh
and Malawi respectively. The results in these studies varied with respect to the frequency
distributions of skin test responses in different groups of populations. The batch-to-batch
variations alone, therefore, cannot explain the different patterns of skin test responses to
these antigens.
It was also noted that the skin test indurations produced by the Rees and Convit skin
tests were extremely soft and needed a considerable amount of training even for standard
readers experienced in reading tuberculin reactions.10 Ponnighaus & Fine, using Rees
antigen (batch CD-19) found almost spontaneous conversions and reversions in a
substantial proportion of the subjects retested.12 This problem would also therefore
contribute to the differences observed in the various studies.
The leprosy epidemiological situation in Venezuela is different in comparison to that
in other areas. Leprosy prevalence in Venezuela is relatively low. There was only one
active case under control per thousand population in 1981.25 In Venezuela it is reported
that the leprosy problem has rapidly declined over the past three decades and that there is
a relative increase in the proportion of multibacillary cases.25 In the Malawi vaccine trial
area. prevalence ofclinical leprosy is found to be about 5 per thousand and multibacillary
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cases constitute about 7% of these cases.26 In our study area the prevalence of leprosy is
around 40-50 per thousand population and about 7% of these cases are of the
multibacillary type.
Categorization of the population into leprosy patients, their contacts and general
population in the present study was based on a prevalence survey. It is possible that some
individuals who might have been leprosy cases and in whom leprosy lesions had
completely resolved at the time of the prevalence survey were considered as non-cases.
The majority of the leprosy patients in the study were of the paucibacillary type, only 7%
belonged to the multibacillary type. As such the majority of the ‘contacts’ belonged to
households with paucibacillary patients. However, the pattern of reactions in contacts of
multibacillary patients was similar to that in contacts of paucibacillary patients. Since the
number of contacts of patients with multibacillary leprosy was small and Rees antigen
positivity in them was not significantly different from that in other contacts, all the
contacts were considered as one group.
Our study area is adjacent to Thiruvallur Taluk in Chengalpattu District, where a
BCG prophylaxis trial against tuberculosis and leprosy was conducted, and which had a
high prevalence of nonspecific sensitivity.15 Thus the study area is expected to have a high
level of nonspecific sensitization. Studies carried out in different parts of lndia have
demonstrated that nonspecific sensitization is not restricted to Chengalpattu District
alone, but is a widespread phenomenon, in the temperate zone the population at higher
altitudes had a lower prevalence of nonspecific sensitivity than that among the population
in the plains. In the tropical zone, prevalence of nonspecific sensitization was high,27-29
however, even in Kashmir valley, situated about 1650 m above the mean sea level,
prevalence of nonspecific sensitivity was 59%.30 It is difficult to say to what extent the
existing high level of nonspecific sensitization in the study area would have influenced the
pattern of results to the skin-test antigens observed by us.
To sum up, the results of the study reported here clearly show that the Rees and the
Convit antigen skin tests are not sensitive enough to detect leprosy, they do not appear to
be specific enough to confirm the clinical diagnosis of leprosy. Since the present study was
conducted in a leprosy endemic area, the differences between contacts of leprosy patients
and the general population might not be evident. Almost every individual in the study
population was exposed to the M. leprae infection. However, the pattern of reactions to
these antigens seen in patients and the almost identical pattern observed in other
population groups, raise serious doubts about their use in detecting M. leprae infection in
a leprosy endemic population with a high prevalence of nonspecific sensitivity.
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